Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders |
Mechanism ALK degraders(Anaplastic lymphoma kinase degraders), Proteolysis |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC55H72ClN9O13S |
InChIKeyVEKJQNCZEPLNJF-UHFFFAOYSA-N |
CAS Registry2230077-10-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | United States | 06 Apr 2022 |





